On May 29, 2020, Larimar Therapeutics, Inc. (the “Company” or “Larimar”) (formerly known as Zafgen, Inc., or “Zafgen”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors. In accordance with the Merger Agreement, on May 28, 2020, immediately prior to the effective time of the Merger, Patricia L. Allen resigned as Chief Financial Officer of Zafgen.